SCHEMBL6880338

SCHEMBL6880338

CSc1ncc(NC(=O)OC(C)(C)C)c(Oc2ccc(F)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAPK1 P53355 1/20 0.43
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
SCN9A Q15858 3/20 0.39
S1PR2 O95136 1/20 0.37
NTRK1 P04629 1/20 0.37
RORC P51449 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
LCK P06239 1/20 0.37
PTGER4 P35408 1/20 0.36
PDE4B Q07343 1/20 0.36
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143099 0.85 MAPT (0.49) DAPK1MAPTKDM4ECYP1A2CYP2C9
SCHEMBL6881285 0.83 NPC1 (0.43) MAPTKDM4ETDP1NPSR1NTRK1
SCHEMBL6881517 0.82 MAPT (0.47) MAPTKDM4ENPSR1NTRK1RXFP1
SCHEMBL6872075 0.79 CYP1A2 (0.51) DAPK1MAPTKDM4ECYP1A2CYP2C9
SCHEMBL10255498 0.76 NTRK1 (0.42) MAPTKDM4ENTRK1RXFP1MEN1
SCHEMBL6880171 0.75 MAPT (0.53) MAPTKDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL1492532 0.75 NTRK1 (0.41) MAPTKDM4ENTRK1LCKMEN1
SCHEMBL2362528 0.73 ALDH1A1 (0.54) MAPTTDP1NPSR1MEN1KMT2A
SCHEMBL21443519 0.72 ALDH1A1 (0.53) MAPTNPSR1MEN1KMT2AALDH1A1
SCHEMBL26341515 0.71 NTRK1 (0.36) MAPTKDM4ENTRK1PDE4BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 DAPK1 4659/4885MAPT 4715/4885KDM4E 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.